Skip to content

Internet Buzz (November 5-6, 2012) About Orphan Drug Company BioMarin Pharmaceutical

November 7, 2012

     Internet buzz (November 5 – 6, 2012) about orphan drug company BioMarin Pharmaceutical : 

1) November 5, 2012 article titled,”BioMarin Jumps as Drug Hits Goals: San Francisco Mover”  

2) November 5, 2012 article titled,”BioMarin Jumps on Late-Stage Trial Results”  

3) November 6, 2012 article titled,”Buyout Buzz: The most frequently cited takeover targets in biotech: BioMarin”

4) November 6, 2012 article titled, ”Orphan drug success puts BioMarin on acquisition agenda”  

5) November 6, 2012 article titled,”BioMarin shares leap on prospect of new drug filing”  

6)  Motley November 5, 2012 article titled,”3 Things to watch with BioMarin”.

      The Novato, California Company, BioMarin Pharmaceutical, has the following orphan drugs on the market in the United States :  

1)  Kuvan (Sapropterin Dihydrochloride) for the treatment of Phenylketonuria (PKU)   

2)  Naglazyme (Galsulfase) for the treatment of Mucopolysaccharidosis VI (MPS VI)    

3)  Aldurazyme (Laronidase) for the treatment of Mucopolysaccharidosis I (MPS I).  

         BioMarin Pharmaceutical has the following orphan drug on the market in the EU :  

1)  Firdapse for the treatment of Lambert-Eaton myasthenic syndrome or LEMS. It is still going through the approval process in the United States. 


BioMarin Pharmaceutical Pipeline  

Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: